论文部分内容阅读
观察33例脑胶质瘤(A组)手术标本中抽取胶质瘤浸润淋巴细胞(GIL),在体外经IL-2激活、培养、扩增3~4周后,经Ommava管回输入肿瘤术后残腔,并配合以放疗、化疗。与同期仅以手术及放、化疗的胶质瘤33例(B组)对照,结果显示:A组1、2、3年生存率分别为95.45%、91.67%和84%,死亡病例平均生存期为27.5个月,显著高于B组(89.47%、81.87%和58.33%,17.44个月)。说明从胶质瘤手术标本中提取GIL,在体外经IL-2激活、培养、扩增后再回输入肿瘤手术残腔,配合放化疗,是一种较为理想的脑胶质瘤综合疗法。
Glioma-infiltrating lymphocytes (GIL) were extracted from 33 cases of glioma (group A). After in vitro activation by IL-2, the cells were cultured and expanded for 3 to 4 weeks, then transplanted via Ommava tube After the residual cavity, and cooperate with radiotherapy and chemotherapy. Compared with the 33 cases of glioma treated with radiotherapy and chemotherapy (group B), the survival rates at 1, 2 and 3 years in group A were 95.45%, 91.67% and 84%, respectively. The mean survival time Was 27.5 months, significantly higher than the B group (89.47%, 81.87% and 58.33%, 17.44 months). It shows that GIL is extracted from glioma surgical specimens, activated by IL-2 in vitro, cultured, amplified and then imported into the residual cavity of tumor surgery. Combined with radiotherapy and chemotherapy, it is an ideal brain glioma comprehensive therapy.